Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
12:05pm, Tuesday, 26'th May 2026
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 19'th May 2026
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 18'th May 2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four pre
EyePoint: DURAVYU's Durability Could Drive Significant Upside
01:58am, Thursday, 14'th May 2026
EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from current levels. DURAVYU, EYPT's lead candidate for wet AMD and DME, has demonstrated a compelling durabi
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
05:51pm, Wednesday, 06'th May 2026
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
09:25am, Wednesday, 06'th May 2026
EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.65 per share a year ago.
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 06'th May 2026
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
07:00am, Wednesday, 29'th Apr 2026
WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock
04:57am, Tuesday, 21'st Apr 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Thursday, 16'th Apr 2026
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
03:07am, Monday, 06'th Apr 2026
Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) by 101.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commis
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
01:32am, Friday, 27'th Mar 2026
Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 16'th Mar 2026
WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
07:05pm, Sunday, 15'th Mar 2026
Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.
